Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Deborah Collyar: What's In It for Patients?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Deborah Collyar: What's In It for Patients?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis

Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer

Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence